BACKGROUND: Inflammatory bowel disease frequently begins during childhood or adolescence. Current tests and procedures for diagnosing and monitoring inflammatory bowel disease are invasive, uncomfortable and costly. Fecal calprotectin is an inflammatory marker tested in several studies including pediatric patients with inflammatory bowel disease. METHODS: A search for articles published up to October 2011 was conducted using MEDLINE and EMBASE databases. We included original English-written articles referred to pediatric patients with inflammatory bowel disease and measured fecal calprotectin levels. We extracted data concerning fecal calprotectin levels in patients with inflammatory bowel disease and in the controls groups, sensitivity, specificity, positive and negative likelihood ratio. RESULTS: Thirty-four studies were included. Fecal calprotectin levels of patients with inflammatory bowel disease are much higher than those of healthy controls or patients with functional disorders or other gastrointestinal diseases. The results vary greatly when taking all studies into consideration. Nevertheless, in cases of newly diagnosed and/or active inflammatory bowel disease, the results are more homogeneous, with high sensitivity and positive likelihood ratio, low negative likelihood ratio, but moderate specificity. Moreover, 50 μg/g seems to be the most proper cut-off point for the fecal calprotectin test. CONCLUSIONS: The fecal calprotectin test could be used for supporting diagnosis or confirming relapse of inflammatory bowel disease in pediatric patients. A positive result could confirm the suspicion of either inflammatory bowel disease diagnosis or inflammatory bowel disease relapse, due to the high sensitivity of the test, but a negative result should not exclude these conditions, due to its moderate specificity.
BACKGROUND:Inflammatory bowel disease frequently begins during childhood or adolescence. Current tests and procedures for diagnosing and monitoring inflammatory bowel disease are invasive, uncomfortable and costly. Fecal calprotectin is an inflammatory marker tested in several studies including pediatric patients with inflammatory bowel disease. METHODS: A search for articles published up to October 2011 was conducted using MEDLINE and EMBASE databases. We included original English-written articles referred to pediatric patients with inflammatory bowel disease and measured fecal calprotectin levels. We extracted data concerning fecal calprotectin levels in patients with inflammatory bowel disease and in the controls groups, sensitivity, specificity, positive and negative likelihood ratio. RESULTS: Thirty-four studies were included. Fecal calprotectin levels of patients with inflammatory bowel disease are much higher than those of healthy controls or patients with functional disorders or other gastrointestinal diseases. The results vary greatly when taking all studies into consideration. Nevertheless, in cases of newly diagnosed and/or active inflammatory bowel disease, the results are more homogeneous, with high sensitivity and positive likelihood ratio, low negative likelihood ratio, but moderate specificity. Moreover, 50 μg/g seems to be the most proper cut-off point for the fecal calprotectin test. CONCLUSIONS: The fecal calprotectin test could be used for supporting diagnosis or confirming relapse of inflammatory bowel disease in pediatric patients. A positive result could confirm the suspicion of either inflammatory bowel disease diagnosis or inflammatory bowel disease relapse, due to the high sensitivity of the test, but a negative result should not exclude these conditions, due to its moderate specificity.
Authors: Annemieke C Nissen; Carlijn E van Gils; Paul P Menheere; Anita M Van den Neucker; Mark A van der Hoeven; Pierre-Philippe Forget Journal: J Pediatr Gastroenterol Nutr Date: 2004-01 Impact factor: 2.839
Authors: Joanne L Grogan; David H Casson; Allyson Terry; Graham C Burdge; Wael El-Matary; A Mark Dalzell Journal: Inflamm Bowel Dis Date: 2011-03-18 Impact factor: 5.325
Authors: Athos Bousvaros; Donald A Antonioli; Richard B Colletti; Marla C Dubinsky; Jonathan N Glickman; Benjamin D Gold; Anne M Griffiths; Gareth P Jevon; Leslie M Higuchi; Jeffrey S Hyams; Barbara S Kirschner; Subra Kugathasan; Robert N Baldassano; Pierre A Russo Journal: J Pediatr Gastroenterol Nutr Date: 2007-05 Impact factor: 2.839
Authors: Philipp Ehlermann; Kai Eggers; Angelika Bierhaus; Patrick Most; Dieter Weichenhan; Johannes Greten; Peter P Nawroth; Hugo A Katus; Andrew Remppis Journal: Cardiovasc Diabetol Date: 2006-03-30 Impact factor: 9.951
Authors: Thomas Vogl; Athanasios Stratis; Viktor Wixler; Tom Völler; Sumita Thurainayagam; Selina K Jorch; Stefanie Zenker; Alena Dreiling; Deblina Chakraborty; Mareike Fröhling; Peter Paruzel; Corinna Wehmeyer; Sven Hermann; Olympia Papantonopoulou; Christiane Geyer; Karin Loser; Michael Schäfers; Stephan Ludwig; Monika Stoll; Tomas Leanderson; Joachim L Schultze; Simone König; Thomas Pap; Johannes Roth Journal: J Clin Invest Date: 2018-04-03 Impact factor: 14.808
Authors: Kamila Stawczyk-Eder; Piotr Eder; Liliana Lykowska-Szuber; Iwona Krela-Kazmierczak; Katarzyna Klimczak; Aleksandra Szymczak; Patrycja Szachta; Katarzyna Katulska; Krzysztof Linke Journal: Arch Med Sci Date: 2015-04-23 Impact factor: 3.318